Summary.-Radiolabelled affinity-purified antibody to carcinoembryonic antigen (CEA) was injected i.v. into immune-suppressed mice carrying xenografts of human breast carcinoma. Its distribution in the tumours was examined by a combination of immunocytochemistry and autoradiography. The antibody interacted predominantly with the CEA in the extracellular tumour space, rather than on the cell membrane or cytoplasm.
Since 1973, CEA has been used as a target for the localization of tumours by radiolabelled antibody. Initial work in animal models of human tumours (Primus et al., 1973; Mach et al., 1974) was followed by application of this technique in patients. Thus, Dykes et al. (1980) Goldenberg et al. (1980) and Mach et al. (1980) injected 1311-labelled affinity-purified antibodies to CEA in patients, and successfully detected CEA-containing primary and metastatic tumours by external radio-imaging. However, the site of binding of the injected anti-CEA antibody to the tumour CEA has never been demonstrated at cellular level.
We have recently studied the kinetics and some of the factors affecting the localization of anti-CEA antibodies in human breast tumours growing as xenografts in immune-suppressed mice (Moshakis et al., 1981a) . Having demonstrated selective homing of antibody in the tumours, a combination of immunocytochemistry and autoradiography was used to: (a) study the distribution of injected anti-CEA antibodies in the tumour at histological level; (b) examine whether the observed in vivo localization was due to antibody-antigen interaction, and (c) demonstrate the site of this interaction.
MATERIALS AND METHODS
Animal model.-Female CBA/lac mice (weighing on average 20 g) of the Institute of Cancer Research were immune-suppressed by thymectomy and total-body irradiation (6 Gy) preceded by i.p. injection of cytosine arabinoside (200 mg/kg) (Steel et al., 1978) .
An established human breast-carcinoma xenograft, HX99, was used throughout the work. Tumours were implanted s.c., bilaterally, in the flanks 1-7 days after irradiation. The tumours have been shown to maintain their human morphology, human chromosome number and histological features (Bailey et al., 1981) . CEA was demonstrated in conventionally prepared tissue sections, using a rabbit antiserum (Ormerod, 1978) and an alkaline phosphatase goat anti-rabbit conjugate, as described elsewhere (Bailey et al., 1982) . The content of CEA in this tumour, as measured after perchloric acid extraction and radio-immunoassay, was found to be 14-0 + 4 0 ,ug/g (mean of 6 tumours) (Moshakis et al., 1981a) .
Antibody preparation and administration. -These have been described in detail by Moshakis et al. (1981a) . Briefly, anti-CEA sera were raised by monthly s.c. injections of a goat witlh 100 ,ug of CEA purified from hepatic metastases of a human colonic carcinoma. The y-globulin fraction of the immune serum aas affinity purified by passing it over a column of CEA (15 mg) covalently bound to Sepharose 4B (10 ml). After waslhing the column wAith 01M PBS, anti-CEA antibodies wN-ere recovered using 6M guanidine HCl in 0IM PBS. The reactivity of the affinity-purified anti-CEA with CEA was confirmed by immunodiffusion and radioimmunoassay. The affinity-purified antibodies wNere labelled writh 12 51, using Chloramine T (Greenwood et al., 1963) . Globulin from a non-immunized goat was labelled by the same method. Typically, an activity of 1 uCi/,tg wAas attained. Sephacryl S-300 column chromatography of the radiolabelled proteins demonstrated the absence of aggregation and products of degradation.
Two-three weeks after tumour implanta- Immunocytochemical staining of slides was also attempted after the ARGs had been prepared. However, the emulsion overlay hindered the development of the immunocytochemical stain.
In addition to the combined ARG/immunocytochemistry slides, each experiment included tumour sections with ARG alone and immunocytochemical staining alone. Each set of ARGs also included sections which had not been labelled with antibody in vivo but had been stained immunocytochemically and processed as described above.
ARGs were examined both by bright-and dark-field illumination.
RESULTS
The immunocytochemical stain revealed that CEA was distributed patchily throughout the tumour. It was in the cell cytoplasm, on the cell membrane, in the necrotic areas and in extracellular spaces especially in areas of low cell density. On ARG, grains were seen mainly within the extracellular spaces. Rarely, grains were seen around the periphery of a tumour cell. Within the limits of resolution of the ARG (which with 12 5I are poor compared to 3H), the tumour-cell cytoplasm was unlabelled. When imm unocytochemistry and ARG were combined on the same section the extracellular spaces which showed high concentrations of ARG grains also stained immunocytochemically for CEA (see Figure) . In contrast there was minimal grain formation in the sections containing normal goat Ig, and the distribution of grains did not correlate with the location of CEA as shown immunocytochemically.
In normal tissues, minimal grain formation with uniform distribution was noted, both with the radiolabelled anti-CEA and radio-labelled normal goat Ig. Positive chemography effects were not produced by the tissue or the immunocytochemical stain.
DISCUSSION
Previous studies of the selective uptake of specific antibodies by tumours have lacked the final proof that the localization observed was due to reaction of antibody with antigen at the site of the tumour. Our study, combining immunocytochemistry and autoradiography, of the uptake of anti-CEA by a xenografted carcinoma of human breast, has demonstrated that the antibody was predominantly in extracellular spaces rich in CEA. The result is consistent with that of Kim et al. (1980) who attributed the localization of anti-AFP in AFP-containing tumours to the "extracellular milieu" of AFP in the tumour, though their claim was not proved histologically.
The specific antibodies react with secreted CEA molecules collected in the extracellular spaces. The antibody reaches the tumour via the blood pool, which also contains secreted CEA. In our previous study (Moshakis et al., 1981a) we measured the formation and clearance of immune complexes from the blood. Despite the presence of such complexes, free Ig was always in excess. Furthermore, the degree of localization of specific antibody depended on the amount of CEA stored in the tumour; the level of circulating CEA was unimportant. Presumably higher levels of immune complexes are formed in the tumour because the local concentration of CEA is higher at that site.
The paucity of labelled antibody on cell membranes could be due either to the inaccessibility of antibody to many of the cell surfaces, or to the lability of the complexes formed. Rosenthal et al. (1980) have shown that CEA anti-CEA complexes are removed from the surface of cultured colon carcinoma cells by endocytosis. Once inside the cell, the antigen antibody complexes would probably be degraded.
Inaccessibility of antibodies to cell surfaces could also explain the lack of studies describing tumour cytotoxicity in vivo by anti-CEA, either alone or conjugated to therapeutic agents. In our experience, anti-CEA ricin conjugates did not cause a worthwhile or persistent cytotoxic effect in vivo in the xenografted tumour (HX 99) used in this study (Thorpe et al., work in progress) . Localization of antibody toxin conjugates in extracellular spaces would be unlikely to give selective cytotoxicity.
It must be emphasized that CEA is only one of several membrane components which might be potential target antigens for tumour localization or therapy The specific localization obtained with anti-CEA is not particularly good. Greatly improved indices of localization have been obtained recently in some other tumours, using newly developed monoclonal antibodies to tumour-cell surfaces (Moshakis et al., 1981b, c; Ballou et al., 1979; Houston et al., 1980) . This paper underlines the value of undertaking autoradiographic studies before embarking on targeted drug therapy.
